<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:7pt Arial, sans-serif; }
 .font1 { font:8pt Arial, sans-serif; }
 .font2 { font:14pt Arial, sans-serif; }
 .font3 { font:21pt Arial, sans-serif; }
 .font4 { font:10pt Times New Roman, serif; }
 .font5 { font:11pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font2">J.P. Morgan</span></p>
<p><span class="font1" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font0" style="font-weight:bold;">07 September 2016</span></p>
<p><span class="font0" style="font-weight:bold;">Isabella Y. Zhao, CFA</span></p>
<p><span class="font0" style="font-weight:bold;">(852) 2800-8534</span></p>
<p><a href="mailto:isabella.zhao@jpmorgan.com"><span class="font0" style="font-weight:bold;">isabella.zhao@jpmorgan.com</span></a></p><a name="caption1"></a>
<h3><a name="bookmark0"></a><span class="font3"><a name="bookmark1"></a>SWOT Analysis</span></h3>
<table border="1">
<tr><td style="vertical-align:top;">
<p><span class="font5" style="font-weight:bold;">Strengths</span></p></td><td style="vertical-align:top;">
<p><span class="font5" style="font-weight:bold;">Weaknesses</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<ul style="list-style:none;"><li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;It owns 30% of Sinopharm, which provides it access to China’s largest distribution network</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Strong R&amp;D team with a staff of 900, which applied for 89 patents in 2015 alone out of which 15 were granted</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Market leading position in pharmaceutical manufacturing focusing on the largest and fastest growing therapeutic areas</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;It is the market leader in glucose control market</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;First mover advantage in hospital sendee space and full coverage of healthcare value-chain may diversify overall business risks</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Gross and Operating margins have been increasing consistently, and are now at their all-time high of 49.5% &amp;&nbsp;11.8% respectively</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Despite the increase in sales, the cost of goods sold has decreased by 6% implying improved productivity and economies of scale.</span></p></li></ul></td><td style="vertical-align:top;">
<ul style="list-style:none;"><li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Lack of outstanding proprietary products with high gross margins</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Pharmaceutical manufacturing business highly dependent on the group’s capability to win tenders from hospitals</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Limited control over the operations of subsidiaries in which Fosun does not own majority stake</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;The growth in Net Sales has slowed down from double digits to single digit in 2015</span></p></li></ul></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font5" style="font-weight:bold;">Opportunities</span></p></td><td style="vertical-align:top;">
<p><span class="font5" style="font-weight:bold;">Threats</span></p></td></tr>
<tr><td style="vertical-align:top;">
<ul style="list-style:none;"><li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Approval and launch of human insulin</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Huge demand explosion to happen in Chinese generic and prescription drug market</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Expansion of product portfolio reach to international markets to develop new sales channels</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Aging Chinese population, increased healthcare spending and increase in per capita disposable income will spur growth in Chinese healthcare sector in the coming years</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Healthcare services market is poised to grow by the highest rate in the Chinese Healthcare sector. So Fosun should strengthen its already dominant position through expansion</span></p></li></ul></td><td style="vertical-align:bottom;">
<ul style="list-style:none;"><li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Difficulty in exiting minority investments due to unfavorable market conditions</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Failure to gain from any future M&amp;A in terms of yield synergies and growth</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Unfavorable government policies on prices of healthcare products and sendees</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Being a drug manufacturer, quality of raw material and finished drug is a huge issue. Any potential health issue can lead to penalties and brand reputation damage</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Raw materials constitute a major portion of total cost for pharmaceutical (around 65-70%), so any fluctuation in price of raw materials could have a huge impact on the bottom line, since the drug prices are already capped by the government</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Huge Chinese pharmaceutical market size will attract international players which will intensify the already stiff market competition</span></p></li></ul></td></tr>
</table>
<p><span class="font0" style="font-weight:bold;">Source: J.P. Morgan</span></p>
<p><span class="font0" style="font-weight:bold;">27</span></p>
</body>
</html>